In addition, serum FGF21 concentrations are increased in patients with non-alcoholic fatty liver disease, and are positively correlated with triglyceride levels, suggesting that FGF21 may be a potential biomarker of non-alcoholic fatty liver disease and be involved in the regulation of triglycerides (23). Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.